Calprotectin in inflammatory bowel disease.

Area of Science:

• Gastroenterology
• Immunology
• Biomarker Research

Background:

• Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, stems from an aberrant immune response in genetically susceptible individuals.
• Current gold standards for IBD diagnosis and management, colonoscopy and histopathology, are invasive and costly.
• Fecal calprotectin has emerged as a promising non-invasive biomarker for IBD.

Purpose of the Study:

• To review studies on fecal calprotectin's efficacy in IBD diagnosis and management.
• To assess fecal calprotectin's potential as a surrogate marker for colonoscopy.
• To discuss laboratory measurement of fecal calprotectin.

Main Methods:

• Literature review of studies investigating fecal calprotectin in IBD.
• Discussion of laboratory measurement techniques for fecal calprotectin.
• Analysis of fecal calprotectin's role in differentiating IBD from IBS, predicting disease activity, and recurrence.

Main Results:

• Fecal calprotectin has been investigated for IBD differentiation from IBS, prediction of endoscopic/histologic activity, and disease recurrence.
• Studies show promising results, but also significant limitations regarding fecal calprotectin's utility.
• The review synthesizes key findings from relevant studies.

Conclusions:

• Fecal calprotectin holds potential as a non-invasive tool in IBD management.
• Its efficacy as a surrogate marker for colonoscopy requires further validation.
• Continued research is essential to fully establish the role of fecal calprotectin in IBD care.